Home » Newsletters » BioWorld Science

BioWorld Science

June 5, 2008

View Archived Issues

Wyeth initiates phase IIIb INTORACT study comparing Torisel plus Avastin for RCC

AstraZeneca submits sNDA to the FDA for Nexium I.V. for injection in peptic ulcer bleeding

FolateImmune regimen active, well tolerated in metastatic renal cell carcinoma

Antitumor activity seen with anti-AGS-16 antibody in vivo

Phase I studies assess effects of TKI-258 on biomarkers in patients with AML, melanoma

GSK completes tender offer for shares of Sirtris

Genentech initiates phase Ib clinical trial of SGN-40 in combination with Velcade

Mentor completes enrollment in phase I study of botulinum toxin type A for cervical dystonia

ThromboGenics and BioInvent report positive results from phase I study of TB-403

Amgen describes novel compounds to treat hyperparathyroidism in recent patent

Pomalidomide data presented at ASCO

Three phase I studies of anticancer agent PR-104 reported

NN-7128 phase I trial completed

Enrollment completed in phase III study of JZP-6 for fibromyalgia

Fast track designation for LX-1032 in carcinoid syndrome

Sepracor completes acquisition of Oryx

Celgene withdraws European MAA for lenalidomide

Critical Therapeutics reports positive results from phase II clinical trial of zileuton injection

New treatment options for diabetic nephropathy imparted in recent Kowa patent

Hemispherx completes enrollment in phase II study of Ampligen as seasonal flu vaccine enhancer

Novel diagnostic agents disclosed in recent patent

Abbott submits application in Japan for Xience V everolimus eluting coronary stent system

Arana and Greenovation enter collaboration agreement to develop anticancer antibodies

FDA grants approval to Bradmer to initiate phase III GLASS-ART trial of Neuradiab in GBM

Novacea presents preliminary findings from of ASCENT-2 data analysis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 9, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...